Literature DB >> 19923144

Outcome of atrial fibrillation among patients with end-stage renal disease.

Che-Yi Chou1, Huey-Liang Kuo, Shu-Ming Wang, Jiung-Hsiun Liu, Hsin-Hung Lin, Yao-Lung Liu, Chiu-Ching Huang.   

Abstract

BACKGROUND: End-stage renal disease (ESRD) patients are more at risk for atrial fibrillation (AF) than the general population. However, the prognosis in ESRD patients with paroxysmal AF (PaAF), permanent AF (PAF) and paroxysmal AF transformed to permanent AF (TAF) is unknown.
METHODS: In this retrospective longitudinal study, all ESRD patients with PaAF, PAF and TAF between January 2001 and December 2007 were reviewed. The development of thromboembolic events (TEE) was analyzed using Kaplan-Meier analysis and Cox regression.
RESULTS: A total of 81 patients with PaAF, 49 patients with PAF and 89 patients with TAF were reviewed. Seventy-two (32.9%) patients developed TEE, and 63 (28.8%) patients died in 36.9 +/- 21.9 months. Patient survival was not significantly different between patients with different types of AF (P = 0.728). Patients with PaAF had a significantly lower TEE-free survival compared to patients with PAF (P = 0.036). In multivariate Cox regression, patients with paroxysmal AF were more at risk for TEE (P = 0.045) with a hazard ratio of 1.61 (95% confidence interval: 1.01-2.58). PaAF and congestive heart failure, hypertension, age older than 75 years, diabetes, and previous stroke or transient ischemic stroke (CHADS(2)) score were independently associated with an increase in TEE risk (P = 0.028 and P = 0.03).
CONCLUSION: Patient survival is not different in patients with paroxysmal and permanent atrial fibrillation. However, patients with paroxysmal AF are more at risk for the development of TEE than those with permanent AF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19923144     DOI: 10.1093/ndt/gfp589

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

Review 1.  Anticoagulants in atrial fibrillation patients with chronic kidney disease.

Authors:  Robert G Hart; John W Eikelboom; Alistair J Ingram; Charles A Herzog
Journal:  Nat Rev Nephrol       Date:  2012-07-24       Impact factor: 28.314

2.  The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation.

Authors:  Simonetta Genovesi; Emanuela Rossi; Daniela Pogliani; Maurizio Gallieni; Andrea Stella; Fabio Badiali; Ferruccio Conte; Sonia Pasquali; Silvio Bertoli; Patrizia Ondei; Giuseppe Bonforte; Claudio Pozzi; Maria Grazia Valsecchi; Antonio Santoro
Journal:  J Nephrol       Date:  2014-01-16       Impact factor: 3.902

Review 3.  Cardiovascular Pharmacogenomics--Implications for Patients With CKD.

Authors:  Larisa H Cavallari; Darius L Mason
Journal:  Adv Chronic Kidney Dis       Date:  2016-03       Impact factor: 3.620

4.  Long-term outcomes of dialysis in patients with chronic kidney disease and new-onset atrial fibrillation: A population-based cohort study.

Authors:  Tung-Wei Hung; Jing-Yang Huang; Gwo-Ping Jong
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.